Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,179.11
+9.94 (+0.85%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
↗
Today 16:05 EDT
Viking's latest program seeks to push the envelope in weight loss efficacy.
Via
The Motley Fool
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?
↗
Today 7:08 EDT
IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.
Via
The Motley Fool
Topics
ETFs
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss
↗
July 17, 2026
There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Via
The Motley Fool
Topics
Intellectual Property
Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setup
↗
July 17, 2026
Via
Chartmill
Eli Lilly & Co. (NYSE:LLY) Passes Navellier’s High-Growth Screen on Strong Earnings and Sales Momentum
↗
July 14, 2026
Via
Chartmill
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win
↗
July 17, 2026
Novo Nordisk is finally getting one up on its biggest rival.
Via
The Motley Fool
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternatives
↗
July 17, 2026
Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.
Via
Benzinga
Why AtaiBeckley Stock Soared Today
↗
July 16, 2026
The psychedelic drugmaker is being acquired.
Via
The Motley Fool
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion
↗
July 16, 2026
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.
Via
The Motley Fool
Topics
Government
Stocks
This GLP-1 Stock Could Double by 2030. Here's Why
↗
July 16, 2026
Investors need to ask tough questions before initiating a position in this biotech company.
Via
The Motley Fool
Why Is GH Research Stock Trading Higher on Thursday?
↗
July 16, 2026
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
Via
Benzinga
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal
↗
July 16, 2026
Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.
Via
Benzinga
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?
↗
July 16, 2026
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.
Via
The Motley Fool
Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF
↗
July 16, 2026
IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.
Via
The Motley Fool
Topics
ETFs
Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover
↗
July 16, 2026
Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.
Via
Investor's Business Daily
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?
↗
July 16, 2026
IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.
Via
The Motley Fool
Topics
ETFs
Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’
↗
July 16, 2026
Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts recommended Vistra, Meta Platforms, and T. Rowe Price.
Via
Benzinga
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?
↗
July 16, 2026
FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Lilly and Novo.
Via
Investor's Business Daily
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Reported Eli Lilly Acquisition Talks (CORRECTED)
↗
July 16, 2026
AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.
Via
Benzinga
If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today
↗
July 15, 2026
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of...
Via
Benzinga
Why Vivosim Labs Shares Are Rocketing on Wednesday?
↗
July 15, 2026
VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.
Via
Benzinga
3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech
↗
July 15, 2026
With investors finally embracing market segments beyond technology, these three Vanguard ETFs are winning.
Via
The Motley Fool
Topics
ETFs
2 Beaten-Down GLP-1 Stocks to Buy on the Dip
↗
July 15, 2026
Don't wait until clinical milestones send their share prices soaring.
Via
The Motley Fool
Can Biogen Score Another Win In Alzheimer's Disease?
↗
July 14, 2026
Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over 18 months.
Via
Investor's Business Daily
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?
↗
July 14, 2026
Eyes are on the rollout of Lilly's new weight loss pill.
Via
The Motley Fool
Cathie Wood Bought $54 Million Worth Of SpaceX Stock Last Week
↗
July 13, 2026
Cathie Wood's ARK Invest was extremely active last week, adding SpaceX and Meta, while selling AMD and Robinhood stock.
Via
Investor's Business Daily
Topics
ETFs
Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
↗
July 13, 2026
Eli Lilly shares are in the spotlight Monday as the company presents new Kisunla data at the AAIC in London.
Via
Benzinga
Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors
↗
July 13, 2026
Two drugs now generate almost two-thirds of the pharmaceutical giant's revenue.
Via
The Motley Fool
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?
↗
July 11, 2026
IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.
Via
The Motley Fool
Topics
ETFs
Which is the Better Choice for Healthcare Investors? IYH or BBH?
↗
July 11, 2026
BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.
Via
The Motley Fool
Topics
ETFs
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.